Zerbaxa Injection, Powder, Lyophilized, For Solution
Product Images NDC 67919-030

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zerbaxa (NDC 67919-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zerbaxa 01)

Chemical structure of the active ingredients ceftolozane and tazobactam shown as a detailed molecular diagram with atoms and bonds, including a sulfate group.*

FDA Label Image

Chemical Structure (Zerbaxa 02)

Chemical structure diagram of the active ingredient associated with ZERBAXA, showing molecular bonds and functional groups including a sulfonyl and a triazole ring as part of the ceftolozane component.*

FDA Label Image

Principal Display Panel (10 Vial Carton)

Packaging label for Zerbaxa 1.5 g per vial (ceftolozane and tazobactam) injection. The label indicates the product is a lyophilized powder for intravenous infusion provided in 10 single-dose vials. Labeler is Merck Sharp & Dohme LLC. Instructions to refrigerate and keep vials in the carton until use are included. The label also mentions sterile and Rx only status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.